Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss

Translational Research

Volumn 153, Issue 1, 2009, Pages 33-43

  Ramidi, Ganga ^a   Khan, Naseer ^a   Glueck, Charles J ^a   Wang, Ping ^a   Goldenberg, Naila ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; METFORMIN;

ABORTION; ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FETUS DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; LIVE BIRTH; MATERNAL DISEASE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 57649102142     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.11.003     Document Type: Article

References (69)

1. Glueck C.J., Wang P., Fontaine R.N., Sieve-Smith L., Tracy T., and Moore S.K. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 48 (1999) 1589-1595
2. Glueck C.J., Phillips H., Cameron D., Sieve-Smith L., and Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 75 (2001) 46-52
3. Glueck C.J., Sieve L., Zhu B., and Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 55 (2006) 345-352
4. Glueck C.J., Wang P., Goldenberg N., and Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 10 (2004) 323-334
5. Jakubowicz D.J., Iuorno M.J., Jakubowicz S., Roberts K.A., and Nestler J.E. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 524-529
6. Glueck C.J., Pranikoff J., Aregawi D., and Wang P. Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil Steril 89 (2008) 625-634
7. Glueck C.J., Wang P., Goldenberg N., and Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 17 (2002) 2858-2864
8. Glueck C.J., Bornovali S., Pranikoff J., Goldenberg N., Dharashivkar S., and Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 21 (2004) 829-836
9. Khattab S., Mohsen I.A., Foutouh I.A., Ramadan A., Moaz M., and Al-Inany H. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 22 (2006) 680-684
10. Zolghadri J., Tavana Z., Kazerooni T., Soveid M., and Taghieh M. Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study. Fertil Steril 90 (2008) 727-730
11. Velazquez E.M., Mendoza S., Hamer T., Sosa F., and Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43 (1994) 647-654
12. Velazquez E.M., Mendoza S.G., Wang P., and Glueck C.J. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 46 (1997) 454-457
13. Sarig G., Younis J.S., Hoffman R., Lanir N., Blumenfeld Z., and Brenner B. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 77 (2002) 342-347
14. Ridker P.M., Miletich J.P., Buring J.E., et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 128 (1998) 1000-1003
15. Brenner B., Hoffman R., Blumenfeld Z., Weiner Z., and Younis J.S. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 83 (2000) 693-697
16. Bick R.L. Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group. Clin Appl Thromb Hemost 6 (2000) 115-125
17. Brenner B., and Kupferminc M.J. Inherited thrombophilia and poor pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 17 (2003) 427-439
18. Kupferminc M.J. Thrombophilia and pregnancy. Reprod Biol Endocrinol 1 (2003) 111
19. Kupferminc M.J., Peri H., Zwang E., Yaron Y., Wolman I., and Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand 79 (2000) 963-967
20. Kupferminc M.J., and Eldor A. Inherited thrombophilia and gestational vascular complications. Semin Thromb Hemost 29 (2003) 185-194
21. Kupferminc M.J., Eldor A., Steinman N., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 340 (1999) 9-13
22. Kupferminc M.J., Many A., Bar-Am A., Lessing J.B., and Ascher-Landsberg J. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. BJOG 109 (2002) 1373-1376
23. Glueck C.J., Kupferminc M.J., Fontaine R.N., Wang P., Weksler B.B., and Eldor A. Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 97 (2001) 44-48
24. Eldor A. Thrombophilia and its treatment in pregnancy. J Thromb Thrombolysis 12 (2001) 23-30
25. Glueck C.J., Gogenini S., Munjal J., Tracy T., Pranikoff J., and Wang P. Factor V Leiden mutation: a treatable etiology for sporadic and recurrent pregnancy loss. Fertil Steril 89 (2008) 410-416
26. Many A., Elad R., Yaron Y., Eldor A., Lessing J.B., and Kupferminc M.J. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol 99 (2002) 684-687
27. Many A., Schreiber L., Rosner S., Lessing J.B., Eldor A., and Kupferminc M.J. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 98 (2001) 1041-1044
28. Gris J.C., Mercier E., Quere I., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103 (2004) 3695-3699
29. Carp H., Dolitzky M., and Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 1 (2003) 433-438
30. Kupferminc M.J., Fait G., Many A., et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 20 (2001) 35-44
31. Rey E., Kahn S.R., David M., and Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361 (2003) 901-908
32. Empson M., Lassere M., Craig J.C., and Scott J.R. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 99 (2002) 135-144
33. Younis J.S., Ohel G., Brenner B., Haddad S., Lanir N., and Ben-Ami M. The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG 107 (2000) 415-419
34. Lee R.M., and Silver R.M. Recurrent pregnancy loss: summary and clinical recommendations. Semin Reprod Med 18 (2000) 433-440
35. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174 (1996) 1584-1589
36. Rai R., Cohen H., Dave M., and Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314 (1997) 253-257
37. Gris J.C., Balducchi J.P., Quere I., Hoffet M., and Mares P. Enoxaparin sodium improves pregnancy outcome in aspirin-resistant antiphospholipid/antiprotein antibody syndromes. Thromb Haemost 87 (2002) 536-537
38. Gris J.C., and Mares P. The long and winding road. towards LMWH for pregnancy loss. J Thromb Haemost 3 (2005) 224-226
39. Huxtable L.M., Tafreshi M.J., and Ondreyco S.M. A protocol for the use of enoxaparin during pregnancy: results from 85 pregnancies including 13 multiple gestation pregnancies. Clin Appl Thromb Hemost 11 (2005) 171-181
40. Sarig G., Blumenfeld Z., Leiba R., Lanir N., and Brenner B. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 94 (2005) 980-985
41. De Carolis S., Ferrazzani S., De Stefano V., et al. Inherited thrombophilia: treatment during pregnancy. Fetal Diagn Ther 21 (2006) 281-286
42. Grandone E., De Stefano V., Rossi E., Cappucci F., Colaizzo D., and Margaglione M. Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants. Blood Coagul Fibrinolysis 19 (2008) 226-230
43. Atiomo W.U., Condon J., Adekanmi O., Friend J., Wilkin T.J., and Prentice A.G. Are women with polycystic ovary syndrome resistant to activated protein C?. Fertil Steril 74 (2000) 1229-1232
44. Tsanadis G., Vartholomatos G., Korkontzelos I., et al. Polycystic ovarian syndrome and thrombophilia. Hum Reprod 17 (2002) 314-319
45. Bar J., Cohen-Sacher B., Hod M., Blickstein D., Lahav J., and Merlob P. Low-molecular-weight heparin for thrombophilia in pregnant women. Int J Gynaecol Obstet 69 (2000) 209-213
46. Brenner B., Bar J., Ellis M., Yarom I., Yohai D., and Samueloff A. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study. Fertil Steril 84 (2005) 770-773
47. Uehara S., Hashiyada M., Sato K., Sato Y., Fujimori K., and Okamura K. Preferential X-chromosome inactivation in women with idiopathic recurrent pregnancy loss. Fertil Steril 76 (2001) 908-914
48. Lee R.M., Branch D.W., and Silver R.M. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 185 (2001) 748-753
49. Babbage S.J., Arkwright P.D., Vince G.S., et al. Cytokine promoter gene polymorphisms and idiopathic recurrent pregnancy loss. J Reprod Immunol 51 (2001) 21-27
50. Glueck C.J., Goldenberg N., Wang P., Loftspring M., and Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 19 (2004) 510-521
51. Glueck C.J., Freiberg R.A., Fontaine R.N., Tracy T., and Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res (2001) 19-33
52. Balasa V.V., Gruppo R.A., Glueck C.J., et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost 81 (1999) 739-744
53. Glueck C.J., Wang P., Kobayashi S., Phillips H., and Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 77 (2002) 520-525
54. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
55. Haffner S.M., Kennedy E., Gonzalez C., Stern M.P., and Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19 (1996) 1138-1141
56. Glueck C.J., Phillips H., Cameron D., et al. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 49 (2000) 845-852
57. Dossenbach-Glaninger A., van Trotsenburg M., Dossenbach M., et al. Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem 49 (2003) 1081-1086
58. Buchholz T., Lohse P., Rogenhofer N., Kosian E., Pihusch R., and Thaler C.J. Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages. Hum Reprod 18 (2003) 2473-2477
59. Glueck C.J., Freiberg R.A., Fontaine R.N., Tracy T., and Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop (2001) 19-33
60. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
61. Glueck C.J., Wang P., Bornovali S., Goldenberg N., and Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism 52 (2003) 1627-1632
62. Sullivan A.E., Silver R.M., LaCoursiere D.Y., Porter T.F., and Branch D.W. Recurrent fetal aneuploidy and recurrent miscarriage. Obstet Gynecol 104 (2004) 784-788
63. Carp H., Feldman B., Oelsner G., and Schiff E. Parental karyotype and subsequent live births in recurrent miscarriage. Fertil Steril 81 (2004) 1296-1301
64. Rai R. Is miscarriage a coagulopathy?. Curr Opin Obstet Gynecol 15 (2003) 265-268
65. Blumenfeld Z., and Brenner B. Thrombophilia-associated pregnancy wastage. Fertil Steril 72 (1999) 765-774
66. Rai R., Backos M., Elgaddal S., Shlebak A., and Regan L. Factor V Leiden and recurrent miscarriage-prospective outcome of untreated pregnancies. Hum Reprod 17 (2002) 442-445
67. Dizon-Townson D.S., Meline L., Nelson L.M., Varner M., and Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 177 (1997) 402-405
68. Younis J.S., Brenner B., Ohel G., Tal J., Lanir N., and Ben-Ami M. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 43 (2000) 31-35
69. Bazzan M., and Donvito V. Low-molecular-weight heparin during pregnancy. Thromb Res 101 (2001) V175-V186